Mental Disorders

274 trials 116 recruiting

Filter these 274 trials by phase, country and sponsor.

Open in Search →

A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy a… Ended

2024-513104-34-00 Major Depressive Disorder 4 2024-11-25
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended

2024-511557-21-00 Major Depressive Disorder (MDD) with Moderate-to-severe 5 2024-11-14
AMEND - Add-on MEmaNtine to Dopamine modulation to improve negative symptoms at first psychosis Ended

2024-513878-21-02 First episode psychosis; ICD-10: F20.x; F22.x; F23.x; F 3 2024-11-11
Effects of DLX-001 on PD, Safety, Tolerability, and PK in Participants with MDD Ended

2024-517139-29-00 Major Depressive Disorder (MDD) 3 2024-11-06
Effect of psilocybin on the positive valence system in treatment-resistant depression: a pilot clinical neuroimaging study Ended

2022-501092-11-00 depression 4 2024-11-05
Cannabidiol for treatment of non-affective psychosis and cannabis use Ended

2024-517630-18-00 Lifetime cannabis use 10 2024-10-08
TSPO ligands in the treatment of depression Ended

2024-512698-29-00 Unipolar/bipolar depressive disorder 4 2024-07-25
Single Ascending Dose study of ENX-104 Ended

2024-514265-19-00 Major Depressive Disorder 1 2024-07-17
A study in healthy volunteers to find out how long aticaprant stays in and acts on the body when administered with or without food and with … Ended

2023-510472-31-00 Healthy Adult Participants 3 2024-07-05
An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants with Schizophrenia Ended

2023-505664-11-00 Schizophrenia 3 2024-06-19
IMPACT-EXT (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD]) Ended

2023-508381-16-00 Post-Traumatic Stress Disorder 4 2024-06-13
An adaptive, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of RL-007 in the treatment of cognitive … Ended

2023-506570-12-01 Cognitive disorder 4 2024-06-13
A study in healthy volunteers to find out how long aticaprant stays in and acts on the body when administered with or without rabeprazole. Ended

2023-510467-35-00 Healthy Adult Participants. 3 2024-06-05
A randomized, two-way, crossover, two parallel groups study to compare the bioavailability of 150 mg and 300 mg trazodone hydrochloride tabl… Ended

2024-511612-24-00 Intended indication: Major Depressive Disorders with an 2 2024-05-31
Long Term Outcomes Ended

2023-505098-34-00 Opioid Use Disorder 6 2024-04-22
The effect of sertraline on anxiety-depressive symptoms, endothelial dysfunction and biomarkers in heart failure patients with preserved eje… Ended

2024-515061-33-00 Depressive-anxiety states in people with heart failure 5 2024-03-22
Psilocybin in alcohol use disorder with comorbid depression - Randomized double-blind controlled pilot study. Ended

2023-506647-42-00 alcohol use disorder 4 2024-02-05
AN OPEN LABEL, TWO PERIODS, TWO SEQUENCES, CROSSOVER, RANDOMIZED MULTIPLE DOSE BIOEQUIVALENCE STUDY OF GUANFACINE 7 MG PROLONGED-RELEASE TAB… Ended

2023-506596-10-00 Study performed on healthy volunteers. 2 2024-01-31
A Study to Assess the Use of Methylone in the Treatment of Post-Traumatic Stress Disorder (PTSD) Ended

2023-505874-14-00 Post-Traumatic Stress Disorder (PTSD) 9 2024-01-16
An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Aticaprant (JNJ-67953964) Ended

2023-503258-11-00 Healthy Adult Participants 3 2023-12-06
An Exploratory, Multicenter, Randomized, double-blind, placebo-controlled study evaluating the effect and safety of pitolisant in children a… Ended

2023-503678-18-00 Autism spectrum disorders 4 2023-10-10
A clinical trial to evaluate the absolute bioavailability and metabolic profile of aticaprant when administered as an oral tablet and a micr… Ended

2022-502969-19-00 Healthy Adult Participants 3 2023-09-27
A Clinical Study that will measure how well SEP-363856 works and how safe it is in adults with Generalized Anxiety Disorder Ended

2022-502077-42-00 generalised anxiety disorder 10 2023-09-14
Study to Evaluate the Efficacy and Safety of Intranasal BPL-003 in Patients with Treatment Resistant Depression Ended

2024-513457-70-00 Treatment-Resistant Depression (TRD) 4 2023-09-08